ProKidney Corp. (PROK) Positioned to Redefine Chronic Kidney Disease Treatment, Believes H.C. Wainwright

Group 1 - ProKidney Corp. (NASDAQ:PROK) is currently rated as a "buy" by over half of analysts, with a median price target of $6.50, indicating a potential upside of 152.92% from the current price [1] - Analyst Joseph Pantginis from H.C. Wainwright has set a price target of $12, suggesting a 367% upside from the current price [1] - The company is focused on a new approach to treating chronic kidney disease with its lead asset, rilparencel, which has the potential to redefine treatment methods [2] Group 2 - Rilparencel is an investigational autologous cell therapy that has shown promising results in Phase 1 and 2 trials, including improvements in estimated glomerular filtration rate (eGFR) and a positive safety profile [3] - The ongoing Phase 3 PROACT 1 trial has received FDA approval to use eGFR slope as a surrogate endpoint, which may facilitate an accelerated regulatory approval process for a Biologics License Application (BLA) [4] - ProKidney Corp. is a clinical-stage biotechnology company based in North Carolina, established in 2015, dedicated to transforming the treatment landscape for chronic kidney disease [5]